IL5 and Alzheimer disease: Interestingly it has recently been reported that an early-term effect of dupilumab treatment on IL-13, IL-4, IL-5 and IL-22 expression is preferentially found in circulating CD4+ CLA+ T cells from AD patients (62, 63).